GSK has revealed that it is likely it will close its Ulverston plant in 2025 – unless an alternative use for the factory is found – it told workers today.
It announced that it has sold its Cephalosporin antibiotics business to Sandoz.
The manufacture will transfer to Sandoz’s manufacturing network after a transfer period of around four years.
A statement from the firm said: “At that time – currently expected to be in 2025 – and in the absence of any alternative, it would be GSK’s proposal to close its Cephalosporins manufacturing operations at Ulverston, Cumbria and the Zinnat building, Barnard Castle, County Durham.”
Manufacture of other products at Barnard Castle would not be affected.
The firm added: “GSK is providing support to potentially affected employees and is committed to supporting the local communities affected by the potential closure of manufacturing facilities in the longer term.”
